PCM
JAZZ icon

Polymer Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Polymer Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,096
Closed -$1.21M – 917
2025
Q4 		$1.21M Buy
+7,096
New +$1.09M 0.13% 197
2025
Q2 		– Sell
-2,445
Closed -$304K – 689
2025
Q1 		$304K Buy
+2,445
New +$319K 0.08% 354

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Polymer Capital Management's JAZZ Position: Q1 2026 in Review

Polymer Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 7,096 shares — an estimated $1.21M sold.

Polymer Capital Management first reported a position in JAZZ in Q1 2025 and held it in 2 quarters. The position peaked at $1.21M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Polymer Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Polymer Capital Management sold 7,096 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.21M.
  • Polymer Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Polymer Capital Management's Jazz Pharmaceuticals position peaked at $1.21M in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.